|
[1]
|
UNAIDS. Global HIV & AIDS statistics — fact sheet. https://www.unaids.org/en/resources/fact-sheet. [2023-04-20]. |
|
[2]
|
Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, De Luca A, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011;11(5):363 − 71. http://dx.doi.org/10.1016/S1473-3099(11)70032-9CrossRef
|
|
[3]
|
Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf. [2022-4-10].https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf |
|
[4]
|
European AIDS Clinical Society. Guidelines version 10.0. 2019. https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf. [2020-3-13].https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf |
|
[5]
|
Ma Y, Dou ZH, Guo W, Mao YR, Zhang FJ, McGoogan JM, et al. The human immunodeficiency virus care continuum in China: 1985–2015. Clin Infect Dis 2018;66(6):833 − 9. http://dx.doi.org/10.1093/cid/cix911CrossRef
|
|
[6]
|
Rose R, Cross S, Lamers SL, Astemborski J, Kirk GD, Mehta SH, et al. Persistence of HIV transmission clusters among people who inject drugs. AIDS 2020;34(14):2037 − 44. http://dx.doi.org/10.1097/QAD.0000000000002662CrossRef
|
|
[7]
|
Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et al. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. Mol Biol Evol 2020;37(5):1530 − 4. http://dx.doi.org/10.1093/molbev/msaa015CrossRef
|
|
[8]
|
World Health Organization. Surveillance of HIV drug resistance in populations initiating antiretroviral therapy (pre-treatment HIV drug resistance): concept note. Geneva: World Health Organization. 2014. https://apps.who.int/iris/handle/10665/112802.https://apps.who.int/iris/handle/10665/112802 |
|
[9]
|
World Health Organization. HIV drug resistance report 2021. Geneva: World Health Organization. 2021. https://www.who.int/publications/i/item/9789240038608.https://www.who.int/publications/i/item/9789240038608 |
|
[10]
|
Hemelaar J, Elangovan R, Yun J, Dickson-Tetteh L, Fleminger I, Kirtley S, et al. Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis. Lancet Infect Dis 2019;19(2):143 − 55. http://dx.doi.org/10.1016/S1473-3099(18)30647-9CrossRef
|
|
[11]
|
Xu JJ, Han MJ, Jiang YJ, Ding HB, Li X, Han XX, et al. Prevention and control of HIV/AIDS in China: lessons from the past three decades. Chin Med J 2021;134(23):2799 − 809. http://dx.doi.org/10.1097/CM9.0000000000001842CrossRef
|
|
[12]
|
He X, Xing H, Ruan YH, Hong KX, Cheng CL, Hu YY, et al. A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey. PLoS One 2012;7(10):e47289. http://dx.doi.org/10.1371/journal.pone.0047289CrossRef
|
|
[13]
|
Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008;13 Suppl 2:25 − 36. http://dx.doi.org/10.1177/135965350801302s04CrossRef
|
|
[14]
|
Zuo LL, Liu K, Liu HL, Hu YH, Zhang ZJ, Qin JR, et al. Trend of HIV-1 drug resistance in China: A systematic review and meta-analysis of data accumulated over 17 years (2001–2017). eClinicalMedicine 2020;18:100238. http://dx.doi.org/10.1016/j.eclinm.2019.100238CrossRef
|
|
[15]
|
Rhee SY, Kassaye SG, Barrow G, Sundaramurthi JC, Jordan MR, Shafer RW. HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates. J Int AIDS Soc 2020;23(9):e25611. http://dx.doi.org/10.1002/jia2.25611CrossRef
|
|
[16]
|
Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009;4(3):e4724. http://dx.doi.org/10.1371/journal.pone.0004724CrossRef
|
|
[17]
|
Rhee SY, Clutter D, Fessel WJ, Klein D, Slome S, Pinsky BA, et al. Trends in the molecular epidemiology and genetic mechanisms of transmitted human immunodeficiency virus type 1 drug resistance in a large US clinic population. Clin Infect Dis 2019;68(2):213 − 21. http://dx.doi.org/10.1093/cid/ciy453CrossRef
|
|
[18]
|
McClung RP, Oster AM, Ocfemia MCB, Saduvala N, Heneine W, Johnson JA, et al. Transmitted drug resistance among Human Immunodeficiency Virus (HIV)-1 diagnoses in the United States, 2014–2018. Clin Infect Dis 2022;74(6):1055 − 62. http://dx.doi.org/10.1093/cid/ciab583CrossRef
|
|
[19]
|
Walter H, Schmidt B, Korn K, Vandamme AM, Harrer T, Überla K. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J Clin Virol 1999;13(1 − 2):71 − 80. http://dx.doi.org/10.1016/s1386-6532(99)00010-4CrossRef
|
|
[20]
|
De Cock KM, Jaffe HW, Curran JW. Reflections on 40 years of AIDS. Emerg Infect Dis 2021;27(6):1553 − 60. http://dx.doi.org/10.3201/eid2706.210284CrossRef
|